Myocardial Injury in One Third of COVID-19 Patients

Roughly one third of patients hospitalized for COVID-19 have some degree of myocardial injury and this comes hand in hand with increased mortality compared against patients with no troponin elevation. 

Manejo de los infartos durante la pandemia de Covid-19

Even mild forms of myocardial injury, such as 0.03 to 0.09 ng/mL troponin elevation, is associated with close to 100% increase in mortality (HR: 1.75; CI 95% 1.37-2.24).

In patients with greater injury (troponins over 0.09 ng/mL) mortality increases over 200% (HR 3.03; CI 95% 2.42-3.80).

This recent observational study soon to be published in JACC included 3069 patients diagnosed with COVID-19, hospitalized in New York.

The aim of this study was to better understand the prevalence of these troponin elevation and its impact on prognosis. 


Read also: Estimating the Risk of Infection for Healthcare Personnel.


Over 90% of patients were measured at least once for troponin-I elevation within 24hrs of admission. 455 of these showed mild elevation (0.03-0.09 ng/mL) and 530 significant elevation (> 0.09 ng/mL). 

Over one third of patients with significant elevation had previously been diagnosed with CAD. Atrial fibrillation and cardiac failure were also prevalent among patients with significant troponin-I elevation. 

The older the patient, the higher the body mass index and disease severity, the higher the mortality rate. After adjusting for covariables, troponin elevation continued to be a clear indicator of worse prognosis. 


Read also: Priorities in the Cath Lab to Escape COVID-19 Tsunami.


One of the limitations to this study was that other than troponin concentration no other tests were carried out, not even a 12-derivation electrocardiogram.      

With this information, we can conclude that troponin elevation is a prognosis marker, though it is hard to speculate about its etiology. 

It could be due to the cytokine storm or because of other acute phase reactants; it might also be the direct impact of the virus as myocarditis, or a non-ischemic myocardial injury due to the demand/offer imbalance, or a common acute coronary syndrome triggered by the inflammatory condition.


Read also: Covid-19 and Unaccounted Collateral Damage.


The COVID-19 pandemic history is being written and we are learning as we go. 

Original Title: Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection.

Reference: Lala A et al. J Am Coll Cardiol. 2020; Epub ahead of print. doi: 10.1101/2020.04.20.20072702.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...

Comparison of strategies: NMA of IVUS, OCT, or angiography in complex lesions

Percutaneous coronary intervention (PCI) in complex lesions continues to represent a technical challenge in contemporary interventional cardiology. Angiography, although it remains the most widely...

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Morpheus Global Registry: Safety and efficacy of the long tapered BioMime™ Morph stent in complex coronary lesions

Percutaneous coronary intervention in long coronary lesions continues to represent a technical and clinical challenge, in which the use of conventional cylindrical stents may...

TEER plus optimal medical therapy versus medical therapy alone in functional mitral regurgitation

Mitral regurgitation (MR) is a highly prevalent valvular heart disease that, in advanced stages and when left untreated, is associated with reduced quality of...

Hybrid Coronary Revascularization versus Conventional Bypass Surgery in Left Main Coronary Artery Disease

Significant left main coronary artery (LMCA) disease continues to represent a therapeutic challenge, particularly in patients with complex multivessel disease and high SYNTAX scores,...